The considerable ownership by retail investors in Corbus Pharmaceuticals Holdings indicates that they collectively have a greater say in management and business strategy A total of 25 investors have a ...

NORWOOD, Mass., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, today ...

Marijuana stocks are practically unstoppable of late, and growth in the legal cannabis industry is catching the attention of investors. Last year, according to cannabis research firm ArcView, sales of ...

Corbus Pharmaceuticals (NASDAQ: CRBP) managed to become one of the top-performing biotech stocks on the market in 2016. Over the last 12 months, Corbus' share price has soared 550%. It was a bumpy ...

Shares of Corbus Pharmaceuticals Holdings (NASDAQ: CRBP) were soaring 11.4% higher as of 3:04 p.m. EDT on Friday. The nice gain came after Jefferies analyst Maury Raycroft initiated coverage on the ...

Investors have been ignoring this cannabis drug company's progress. Inflammatory and fibrotic, or scarring, diseases arise when the body's immune system goes out of control. Inflammation is the ...

Corbus Pharmaceuticals (CRBP) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is ...

NORWOOD, Mass., Oct. 31, 2025 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (Nasdaq: CRBP) (“Corbus” or the “Company”), an oncology and obesity company, today announced the pricing of an ...

Shares of Corbus Pharmaceuticals Holdings, Inc. CRBP fell 35.9% after it announced disappointing top-line results from its 28-week phase IIb study of lenabasum in patients with cystic fibrosis (CF).

Four years ago, Corbus Pharmaceuticals claimed success in a mid-stage clinical trial of its lead drug, lenabasum, announcing that it improved symptoms in patients with a chronic, connective tissue ...